Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.76
+0.13000.16%
Post-market: 82.760.00000.00%17:36 EDT
Volume:1.02M
Turnover:84.39M
Market Cap:11.66B
PE:-36.24
High:83.38
Open:81.58
Low:80.33
Close:82.63
52wk High:95.49
52wk Low:27.94
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.57
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:25.04
PE(LYR):-6,787.50

Loading ...

Arrowhead initiated with a Buy at Stifel

TIPRANKS
·
Jul 14

Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's?

Dow Jones
·
Jul 13

Arrowhead Pharmaceuticals Inc Stock (ARWR) Moved Down by 7.27% on Jul 10: What Signal Does It Send?

TradingKey
·
Jul 11

Movement Alert|Arrowhead Research Corporation Falls 7.92% in Regular Trading, Trading at $77.45

Market Focus
·
Jul 11

Arrowhead Pharmaceuticals (ARWR) Is Up 6.6% After Russell Index Upgrade Has The Bull Case Changed?

Simply Wall St.
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), Tarsus Pharmaceuticals (TARS) and Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jul 06

Arrowhead Pharmaceuticals (ARWR) Joins Larger Indexes After EU Approval, Is It Still Cheap?

Simply Wall St.
·
Jul 06

Is EU REDEMPLO Approval For Clinically Diagnosed FCS Patients Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

Simply Wall St.
·
Jul 02

Arrowhead Pharmaceuticals Price Target Maintained with a $100.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 02

Arrowhead Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 30

Arrowhead Pharmaceuticals (ARWR) Receives a Buy from Piper Sandler

TIPRANKS
·
Jun 30

Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (ARWR) and CSL (OtherCMXHF)

TIPRANKS
·
Jun 30

Arrowhead Pharmaceuticals Posts Cardiometabolic R&D Webinar Presentation

Reuters
·
Jun 30

Analysts’ Top Healthcare Picks: Eton Pharmaceuticals (ETON), Arrowhead Pharmaceuticals (ARWR)

TIPRANKS
·
Jun 27

Arrowhead receives MAA in the EU for REDEMPLO

TIPRANKS
·
Jun 23

Arrowhead says EU grants marketing authorization for REDEMPLO in adult FCS patients

Reuters
·
Jun 23

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for Redemplo® (Plozasiran) to Reduce Triglycerides in Adults With Familial Chylomicronemia Syndrome (Fcs)

THOMSON REUTERS
·
Jun 23

Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update

Simply Wall St.
·
Jun 20

Arrowhead Pharmaceuticals to host cardiometabolic R&D webinar in 2026 Summer Series

Reuters
·
Jun 18

Arrowhead Pharma director Matthew Gregory Cohen files initial beneficial ownership statement

Reuters
·
Jun 18